专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130137729A1 USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE 审中-公开
标题翻译：利福平，卡比多巴和恩替卡松治疗帕金森病的应用
公开(公告)号：US20130137729A1
公开(公告)日：2013-05-30
申请号：US13582427
申请日：2011-03-03
申请人： Juha Rouru , Mikko Kuoppamäki , Juha Ellmen , Pekka Männistö
发明人： Juha Rouru , Mikko Kuoppamäki , Juha Ellmen , Pekka Männistö
IPC分类号： A61K31/198 , A61K31/12 , A61K31/4439 , A61K31/277 , A61K31/165
CPC分类号： A61K31/277 , A61K9/2077 , A61K9/286 , A61K31/165 , A61K31/198 , A61K31/4439 , A61K45/06 , A61K2300/00
摘要： The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising (i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and (iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage forms used in said methods are also disclosed.
摘要翻译：本公开内容提供了一种治疗帕金森病的方法，其包括同时或依次给予需要治疗帕金森病的患者一种剂型，其包含（i）量为50mg至300mg的左旋多巴，（ii）卡比多巴其量为25mg至150mg或治疗当量的另一种芳族氨基酸脱羧酶抑制剂，和（iii）量为50mg至300mg的恩他卡朋，其中所述剂型中恩他卡朋与卡比多巴的比例的范围为0.3:1.0至3.2:1.0的中等强度的COMT抑制剂，其量为25mg至200mg，其中所述剂型中所述COMT抑制剂与卡比多巴的比例为0.16:1.0至3.08:1.0 或高效COMT抑制剂，其量为1mg至100mg，其中所述剂型中所述COMT抑制剂与卡比多巴的比例范围为0.006:1.0至1.54:1.0 ght。还公开了用于所述方法的药物剂型。

IPRDB

热门服务

关于我们

友情链接

联系方式